Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Condensed Consolidated Statements Of Operations    
Revenues
Operating expenses:    
General and administrative 79,843 133,353
Total operating expenses 79,843 133,353
Loss from operations (79,843) (133,353)
Other income (expense):    
Loss on fair value adjustment - derivatives (313,419)
Interest expense (64,027) (45,527)
Accretion (amortization) of interest - beneficial conversion feature 3,500
Total other income (expense) (64,027) (355,446)
Loss before provision for income taxes (143,870) (488,799)
Provision for income tax
Net loss (143,870) (488,799)
Less: Net loss attributable to noncontrolling interest 821 965
Net loss attributable to TranBioTec, Inc. $ (143,049) $ (487,834)
Net loss per share    
(Basic and fully diluted) $ (0.001) $ (0.007)
Weighted average number of common shares outstanding 109,409,930 74,200,854